Simultaneous or Rapid Sequence Optimization of Medical Therapy for Heart Failure: Time to Keep Score
- PMID: 40799134
- DOI: 10.1161/CIRCHEARTFAILURE.125.013417
Simultaneous or Rapid Sequence Optimization of Medical Therapy for Heart Failure: Time to Keep Score
Keywords: Editorials; heart failure; quality improvement; therapy.
Conflict of interest statement
Dr Fonarow reports consulting for Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Eli Lilly, Johnson & Johnson, Medtronic, Merck, Novartis, and Pfizer. Dr Greene has received research support from the American Heart Association, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Otsuka, Pfizer, and Sanofi; has served on advisory boards or as consultant for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Corcept Therapeutics, Corteria Pharmaceuticals, CSL Vifor, Cytokinetics, Idorsia, Lexicon, Lilly, Merck, Novo Nordisk, Otsuka, Recordati, Roche Diagnostics, Sanofi, scPharmaceuticals, Sumitomo, Tricog Health, and Viatris; and has received speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Lexicon, Novo Nordisk, and Roche Diagnostics. The other author reports no conflicts.
Comment on
-
Guideline-Directed Medical Therapy Use in the STRONG-HF Trial.Circ Heart Fail. 2025 Sep;18(9):e012716. doi: 10.1161/CIRCHEARTFAILURE.124.012716. Epub 2025 Jul 3. Circ Heart Fail. 2025. PMID: 40605744 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources